Jagsonpal Pharmaceuticals extinguishes 16 lakh shares
Jagsonpal Pharmaceuticals Limited extinguished 16,00,000 equity shares on June 02, 2026, pursuant to SEBI Buy-Back Regulations. The share capital reduced to ₹13,10,78,300, with promoter holding increasing to 69.36%.

*this image is generated using AI for illustrative purposes only.
Jagsonpal Pharmaceuticals Limited has extinguished 16,00,000 equity shares following the completion of its buyback offer on June 02, 2026. The extinguishment was carried out on a proportionate basis through the tender offer route pursuant to the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018. This corporate action reduces the total number of issued, subscribed, and fully paid-up equity shares from 6,71,39,150 to 6,55,39,150, bringing the post-buyback share capital to ₹13,10,78,300.
Share Capital Reconciliation
The reconciliation of the company's share capital pre and post-extinguishment confirms that all 16,00,000 shares bought back were in dematerialized form, with no shares tendered in physical form. The equity shares extinguished carry a face value of ₹2 each. The process was verified by the Registrar to the Buyback Offer, MCS Share Transfer Agent Limited, and certified by the company's Managing Director and Non-Executive Director in compliance with Regulation 11 of the Buyback Regulations.
| Particulars | No. of Equity Shares | Amount (in ₹) |
|---|---|---|
| Pre-extinguishment: Issued, subscribed and fully paid-up share capital | 6,71,39,150 | 13,42,78,300 |
| Less: Equity Shares bought-back (Dematerialized Form) | 16,00,000 | 32,00,000 |
| Post extinguishment: Issued, subscribed and fully paid-up share capital | 6,55,39,150 | 13,10,78,300 |
Depository Confirmations
National Securities Depository Limited (NSDL) executed the debit of 1,600,000 equity shares on May 27, 2026. Central Depository Services (India) Limited (CDSL) also confirmed the buyback, noting that the capital of the company recorded with CDSL post-buyback stands at ₹13,10,78,300. The extinguishment was finalized based on the public announcement dated April 28, 2026, and the letter of offer dated May 6, 2026.
Shareholding Pattern Post-Buyback
The extinguishment of shares has altered the shareholding pattern of the company. The Promoter and Promoter Group's holding has increased to 69.36% of the post-buyback equity share capital, while Foreign Investors now hold 30.64%. The total number of equity shares post-buyback stands at 6,55,39,150.
| Category | Pre-Buyback Shares | % of Pre-Buyback Capital | Post-Buyback Shares | % of Post-Buyback Capital |
|---|---|---|---|---|
| Promoter / Promoter Group | 4,54,58,210 | 67.71 | 4,54,58,210 | 69.36 |
| Foreign Investors | 22,37,115 | 3.33 | 2,00,80,940 | 30.64 |
| Financial Institutions / Banks & Mutual Funds | 4,30,091 | 0.64 | - | - |
| Others (Public, Public Bodies Corporate etc.) | 1,90,13,734 | 28.32 | - | - |
| Total | 6,71,39,150 | 100.00 | 6,55,39,150 | 100.00 |
Historical Stock Returns for Jagsonpal Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.12% | -2.84% | -3.98% | -7.23% | -14.79% | +294.05% |
How will the significant increase in Foreign Investors' stake to 30.64% influence Jagsonpal's strategic direction and governance?
What impact will the reduced equity base have on the company's earnings per share (EPS) and future dividend payouts?
Will the company consider further capital allocation strategies, such as dividends or additional buybacks, given the promoter group's increased holding?


































